Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | RO7121661 |
Synonyms | |
Therapy Description |
RO7121661 is a bispecific antibody that binds to PD-1 (CD279) and TIM-3 and inhibits ligand interaction, potentially resulting in the activation of cytotoxic T-lymphocytes and increased tumor cell death (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
RO7121661 | RG 7769|RG7769|RG-7769|RO-7121661|RO 7121661|Lomvastomig | Immune Checkpoint Inhibitor 149 PD-L1/PD-1 antibody 122 TIM-3 Antibody 9 | RO7121661 is a bispecific antibody that binds to PD-1 (CD279) and TIM-3 and inhibits ligand interaction, potentially resulting in the activation of cytotoxic T-lymphocytes and increased tumor cell death (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03708328 | Phase I | RO7121661 | A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors | Completed | USA | NZL | FRA | ESP | DNK | 1 |
NCT04785820 | Phase II | RO7121661 Nivolumab RO7247669 | A Study of RO7121661 and RO7247669 Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus | Active, not recruiting | TUR | POL | ITA | HUN | GBR | FRA | ESP | DNK | CZE | BRA | ARG | 7 |